![Brian Underdown](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Brian Underdown
Verkställande Direktör på
MedInnova Partners, Inc.
Profil
Brian J.
Underdown is currently the Chief Executive Officer at MedInnova Partners, Inc., Director at Kisoji Biotechnology, Inc., Director at Naegis Pharmaceuticals, Inc., Venture Partner at Lumira Capital Investment Management, Inc., and President at DC Bio Corp.
He previously held positions such as President & Chief Executive Officer at MedTech Partners, Inc., Chairman at Ontario Genomics Institute, and Independent Director at Argos Therapeutics, Inc. He also served as a Director at various companies including ID Biomedical Corp., Aptose Biosciences, Inc., enGene, Inc., Cytochroma, Inc., Ception Therapeutics, Inc., Excaliber Enterprises Ltd., VistaGen Therapeutics, Inc., Ellipsis Neurotherapeutics, Inc., PainCeptor Pharma Corp., Protiva Biotherapeutics, Inc., TransMolecular, Inc., Trillium Therapeutics, Inc., Viron Therapeutics, Inc., and Natrix Separations, Inc. He was also an Associate Dean at McMaster University and the University of Toronto Faculty of Medicine.
He holds a doctorate from McGill University and a graduate degree from Washington University School of Medicine.
Aktiva positioner av Brian Underdown
| Företag | Position | Start |
|---|---|---|
MedInnova Partners, Inc.
 MedInnova Partners, Inc. Investment ManagersFinance MedInnova Partners provides financing for seed and early-stage capital requirements. The firm focuses on pharma and health care businesses located in Canada. | Verkställande Direktör | - |
DC Bio Corp.
 DC Bio Corp. BiotechnologyHealth Technology Develops technology for application to cancer and diseases associated with chronic viral infections | President | - |
Kisoji Biotechnology, Inc.
 Kisoji Biotechnology, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops cancer therapeutics through antibodies and stem cells | Direktör/Styrelseledamot | - |
Naegis Pharmaceuticals, Inc.
 Naegis Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Develops therapies for retinal and inflammatory eye diseases | Direktör/Styrelseledamot | - |
Lumira Capital Investment Management, Inc.
 Lumira Capital Investment Management, Inc. Investment ManagersFinance LUMIRA invests in revenue stage companies that are both privately held and publically traded companies located in the Canada and the United States. The firm focuses on sectors of therapeutic products and medical devices. It participates in the early stage capital financing. | Privat kapitalinvesterare | - |
Tidigare kända positioner av Brian Underdown
| Företag | Position | Slut |
|---|---|---|
OsteoqQC, Inc.
 OsteoqQC, Inc. BiotechnologyHealth Technology Develops drugs for the treatment of bone-related diseases | Direktör/Styrelseledamot | 2022-12-23 |
| VISTAGEN THERAPEUTICS, INC. | Direktör/Styrelseledamot | 2021-07-21 |
| ARGOS THERAPEUTICS, INC. | Direktör/Styrelseledamot | 2016-03-14 |
| APTOSE BIOSCIENCES INC. | Direktör/Styrelseledamot | 2014-12-15 |
| ░░░░░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Brian Underdowns utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
59
Första gradens relationer
34
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 34 |
|---|---|
ID Biomedical Corp.
 ID Biomedical Corp. Medical SpecialtiesHealth Technology Develops gene-based disease testing and subunit vaccines | Health Technology |
Aptose Biosciences, Inc.
 Aptose Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Discovers, research and develops anticancer therapies with high safety profiles | Health Technology |
enGene, Inc.
 enGene, Inc. BiotechnologyHealth Technology Operates as clinical-stage biotechnology company, which develops non-viral gene therapies | Health Technology |
Cytochroma, Inc.
 Cytochroma, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets prescription products for the prevention of vitamin D insufficiency | Health Technology |
Ception Therapeutics, Inc.
 Ception Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Excaliber Enterprises Ltd.
 Excaliber Enterprises Ltd. Internet Software/ServicesTechnology Services Sells gift baskets via the Internet | Technology Services |
Lumira Capital Investment Management, Inc.
Lumira Capital Investment Management, Inc. Investment ManagersFinance LUMIRA invests in revenue stage companies that are both privately held and publically traded companies located in the Canada and the United States. The firm focuses on sectors of therapeutic products and medical devices. It participates in the early stage capital financing. | Finance |
Argos Therapeutics, Inc.
 Argos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes personalized immunotherapies for the treatment of cancer and infectious diseases | Health Technology |
McGill University
 McGill University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vistastem, Inc.
 Vistastem, Inc. BiotechnologyHealth Technology Develops embryonic stem cells for drug discovery and development | Health Technology |
Ellipsis Neurotherapeutics, Inc.
 Ellipsis Neurotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
McMaster University
 McMaster University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
PainCeptor Pharma Corp.
 PainCeptor Pharma Corp. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which engages in the development of pharmaceuticals for chronic and acute pain | Health Technology |
MedInnova Partners, Inc.
MedInnova Partners, Inc. Investment ManagersFinance MedInnova Partners provides financing for seed and early-stage capital requirements. The firm focuses on pharma and health care businesses located in Canada. | Finance |
MedTech Partners, Inc.
 MedTech Partners, Inc. Investment ManagersFinance MTP generally invests in research and technologies at an early stage of development, even prior to a full evaluation of commercial potential. Selection criteria include the potential size of the market, the credibility and efforts of the principal investigators, the uniqueness of the discovery and the patentability of the discovery. Investments are made by MTP or cover costs relating to patenting, demonstration of proof-of-principle, prototype development and market analysis. | Finance |
Protiva Biotherapeutics, Inc.
 Protiva Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
TransMolecular, Inc.
 TransMolecular, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes novel & proprietary products | Health Technology |
Trillium Therapeutics, Inc. /Old/
 Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Provides research and development of pharmaceuticals | Commercial Services |
Viron Therapeutics, Inc.
 Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel therapeutics for inflammatory disorders | Health Technology |
Medical Discovery Management Corp.
 Medical Discovery Management Corp. Investment ManagersFinance Medical Discovery Management Corp. manages the Canadian Medical Discoveries Fund (CMDF), a venture capital fund focused on the health science sector including life sciences, biotechnology, diagnostics, medical devices, drug discovery and development, health care delivery services and e-health. The Fund invests in technologies and intellectual property that are significant in the global marketplace and focuses on businesses involved in the testing and development or production and commercialization stages of development which have significant potential for growth. CMDF seeks investments that will provide at least a 30% annualized return. Expected time horizon for a liquid market, merger or acquisition is 2 to 4 years | Finance |
Pasteur Mérieux Connaught | |
NATRIX Separations, Inc.
 NATRIX Separations, Inc. Medical SpecialtiesHealth Technology Manufactures and supplies single use and multi-cycle disposable chromatography products | Health Technology |
DC Bio Corp.
DC Bio Corp. BiotechnologyHealth Technology Develops technology for application to cancer and diseases associated with chronic viral infections | Health Technology |
Mcmaster Innovation Park
 Mcmaster Innovation Park Miscellaneous Commercial ServicesCommercial Services Operates as commercial and medical research center | Commercial Services |
Ontario Genomics Institute
 Ontario Genomics Institute Miscellaneous Commercial ServicesCommercial Services Operates as a non-profit organization that catalyzes genomics-based innovation to drive economic growth | Commercial Services |
Canadian Network for Vaccines & Immunotherapeutics | |
VistaGen Therapeutics, Inc.
 VistaGen Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops central nervous system therapies | Health Technology |
Bristol-Myers Squibb FCT bêta, Inc.
 Bristol-Myers Squibb FCT bêta, Inc. Pharmaceuticals: MajorHealth Technology Develops anti-tumor activity medication treatment | Health Technology |
Aimmune Therapeutics, Inc.
 Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Engages in the development of desensitization treatments for peanut and food allergies | Health Technology |
Washington University School of Medicine
 Washington University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Toronto Faculty of Medicine
 University of Toronto Faculty of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kisoji Biotechnology, Inc.
Kisoji Biotechnology, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops cancer therapeutics through antibodies and stem cells | Health Technology |
Naegis Pharmaceuticals, Inc.
Naegis Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Develops therapies for retinal and inflammatory eye diseases | Commercial Services |
OsteoqQC, Inc.
OsteoqQC, Inc. BiotechnologyHealth Technology Develops drugs for the treatment of bone-related diseases | Health Technology |
![\"G](\"https://www.zonebourse.com/images/ImagesTagged/GD/2026/google/Google__G__logo.svg\"){kind=logo}
Välj MarketScreener 
